Autor: Piątkiewicz, Paweł - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: WYKORZYSTANIE MONITORINGU MEDIÓW W BADANIACH EKSTREMIZMU POLITYCZNEGO
THE APPLICATION OF MEDIA MONITORING IN POLITICAL EXTREMISM RESEARCH
Autorzy:: GAWROŃSKI, SŁAWOMIR
Piątkiewicz, Paweł
Powiązania:: https://bibliotekanauki.pl/articles/513104.pdf
Data publikacji:: 2018
Wydawca:: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Tematy:: media monitoring,
political extremism,
media studies
Opis:: The article presents the possibilities provided by applying media studies (media monitoring) in political studies. The author showcases theoretical connections between the impact of mass media and the phenomenon of political extremism. It also presents a case study – a research project carried out in Liechtenstein regarding the monitoring of political extremism. The article contains recommendations for the possible implementa-tion of the project in other countries. The research methods appliedwere limited to the analysis of literature in the field of political extremism and the methods of media studies. The desk research method was also used for the case study.
Źródło:: Polityka i Społeczeństwo; 2018, 16, 3; 7-18 (12)
1732-9639
Pojawia się w:: Polityka i Społeczeństwo
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: Autoimmunity markers in subjects with diabetes
Autorzy:: Litwińczuk-Hajduk, Joanna
Bernat-Karpińska, Małgorzata
Kowrach, Marek
Cielecka-Kuszyk, Joanna
Piątkiewicz, Paweł
Powiązania:: https://bibliotekanauki.pl/articles/972601.pdf
Data publikacji:: 2016
Wydawca:: Instytut Medycyny Wsi
Tematy:: diabetes
anty-GAD
ANA
ASMA
APCA
Opis:: Introduction. Diabetes is a growing social and epidemiological problem. Accordingly, the incidence of complications associated with diabetes can cause a persistent high percentage of diseases of the cardiovascular system, kidney and nervous systems, and impaired vision. Objective. The aim of the study was to evaluate the incidence of immunological markers in patients with type 1 diabetes and those with type 2 diabetes: the anti-GAD, ANA, AMA, ASMA, APCA and LKM, compared to healthy people. Another objective of the study was to evaluate the correlation between their presence and the degree of metabolic control in both groups. Materials and methods. The study comprised 100 subjects aged 25–75 years with a body mass index (BMI) between 20–30 kg / m2, hospitalized in the Department of Internal Diseases, Diabetology and Endocrinology, at the Medical University of Warsaw, with previously diagnosed diabetes who were assigned to one of 2 groups (50 subjects with type 1 diabetes and 50 subjects with type 2 diabetes). The control group consisted of 21 healthy individuals without the diagnosis of diabetes and a prediabetic state. All the study participants had the examined antibodies determined along with the panel of biochemical tests and neurological examination for diabetic neuropathy and fundus examination. Results. Anti-GAD antibodies were present in both groups of patients. Their presence was found in 30% of people with type 1 diabetes and in 16% of people with diabetes type 2. The presence of ANA antibodies was found in 24% of people with type 1 diabetes and 22% of people with type 2 diabetes. There was no correlation between the presence of ANA antibodies ANA and duration of diabetes. In the group of patients with type 1 diabetes, there was a correlation between the presence of ANA and the incidence of diabetic polyneuropathy. ASMA and APCA antibodies occurred with equal frequency in both studied groups (4% vs. 10%). There were no antibodies of AMA or anti-LKM in any of the patients. Conclusions. Marking of ANA antibodies in patients with type 1 diabetes may be a marker used to isolate a group of patients at risk of developing diabetic neuropathy. The presence of anti-GAD in type 2 diabetes may be a LADA marker which specifically marks the group of patients with type 2 diabetes, in whom there is a faster metabolic death of beta cells. The current classification of diabetes is vague, and in the near future it should be modified based on specific patient characteristics, phenotypic appearance, as well as the results of additional tests. Determination of antibodies AMA, ASMA, APCA and anti-LKM does not seem to be significant in the diagnosis of diabetes and its chronic complications.
Źródło:: Journal of Pre-Clinical and Clinical Research; 2016, 10, 1; 28-33
1898-2395
Pojawia się w:: Journal of Pre-Clinical and Clinical Research
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 3.

Tytuł:: Levels of interleukin-2 in patients with colon cancer and diabetes type 2
Autorzy:: Bosek, Irina
Sulich, Agnieszka
Rabijewski, Michał
Kaleta, Beata
Kniotek, Monika
Miłek, Tomasz
Piątkiewicz, Paweł
Powiązania:: https://bibliotekanauki.pl/articles/972606.pdf
Data publikacji:: 2016
Wydawca:: Instytut Medycyny Wsi
Tematy:: diabetes type 2
colon cancer
interleukin-2
Opis:: Introduction and objective: The risk of development colon cancer (CC) is increased significantly among patients with the type 2 diabetes (T2DM). A mechanism responsible for the higher prevalence of CC among diabetic patients may be associated with the immunity system. The aim of this study is to point out the differences in the immunity state in terms of interleukin 2 level among patients with T2DM suffering from CC, and patients without these diseases Material and Methods: 79 patients were included the tests, divided into 4 groups: Group 1–23 people with T2DM, Group 2–23 people with large intestine CC, Group 3–10 people with large CC and T2DM, and Group 4–23 people without T2DM or CC. Each patient had a colonoscopy and those with cancer were confirmed in a histopathological examination. Laboratory measurements included fasting glucose, insulin, C-peptide. The concentration of interleukin-2 in serum was determined with the immunoenzymatic (ELISA) method. Results: The results obtained showed that in patients with T2DM and CC the concentration of interleukin-2 was statistically higher than in the other groups.(4.21±1.61 pg/ml vs. Group 1 -1.64±0.44 pg/ml, Group 2–1.54±0.21 pg/ml, and Group 4–1.70±0.36 pg/ml; p<0.05). Insulin levels, C-peptide and HOMA-IR did not differ significantly between groups, but a tendency was observed to higher values of HOMA-IR and insulin levels in the groups with T2DM alone and T2DM with concomitant CC. Conclusions: The data show differences in the immunity state of patients with T2DM and CC, compared with people without those two diseases. Elevated level of interleukin 2 found in this group, after confirmation in other studies with more patients, could be used as a marker of an increased risk of CC in people with T2DM
Źródło:: Journal of Pre-Clinical and Clinical Research; 2016, 10, 1; 1-5
1898-2395
Pojawia się w:: Journal of Pre-Clinical and Clinical Research
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "Piątkiewicz, Paweł" wg kryterium: Autor

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język